Searched for
ARIHANT CAPITAL
ETMarkets Smart Talk| From floor trading to AI algos: Why India’s retail traders are entering the automation era, says Shruti JainAI-powered algorithmic trading is becoming increasingly accessible to Indian retail investors, driven by Sebi’s regulatory framework, tradi...- Dividends and stock splits: Hindustan Copper, Cochin Shipyard among 200+ stocks with record dates this week. Check full listOver 90 companies have fixed September 18 as the record date for dividends and other corporate actions. Victoria Mills leads with a Rs 50 p...
- Kanohar Electricals IPO Day 3: GMP signals 35% premium, subscription crosses 190xKanohar Electricals IPO entered its final bidding day after being subscribed 10.22 times by Day 2. A 35% grey market premium and positive b...
- Kanohar Electricals IPO Day 2: Issue subscribed 10x, GMP signals 35% premium. Should you bid?Kanohar Electricals IPO received robust demand on its second day of bidding. The issue was subscribed 10.22 times overall, indicating stron...
- SIFs attract Rs 22,328 crore since launch. Should mutual fund investors use them as satellite allocation?Since their inception, Specialised Investment Funds have garnered considerable attention from investors looking for more than what typical ...
- Largecaps look better as smallcaps price in strong growth: Franklin Templeton’s Arihant JainLargecap stocks offer a better risk-reward balance than mid- and small-caps as higher growth expectations are already priced into smaller c...
- Nifty’s 21-day calm before the storm? History warns of a sharp move aheadNifty 50’s August 2026 stability historically signals significant volatility ahead. With future direction unclear, analysts advise shifting...
- Market chaos after CAS: What exactly is Sebi reviewing and will it stop expiry-day wild swings?Sebi’s review of derivative settlement price methodology could reduce sharp expiry-day swings linked to the Closing Auction Session (CAS). ...
- Largecap mutual funds trail mid and smallcaps in 2026. Should investors change strategy?Despite large-cap mutual funds showing a decline this year, mid and small-cap funds have proven to be winners. Experts advise investors to ...
- Eligible for 75% EPF balance withdrawal and planning to do so? Think again and find out how much it will cost you to rebuild itNew EPF withdrawal rules offer greater flexibility for salaried employees. Experts caution against withdrawing retirement savings premature...
- Manipal Health Enterprises IPO Day 2: GMP holds at 2%, Subscription reaches 15%. Should you Subscribe or Skip?Manipal Health Enterprises' large IPO is experiencing cautious investor interest on its second day. The grey market premium remains modest,...
- Manipal Health’s Rs 9,275 crore IPO opens for subscription. Should you apply?Manipal Health Enterprises' Rs 9,275-crore IPO opened for subscription on July 29 with a muted grey market premium of around 2%, signalling...
- Hybrid SIFs: How these specialised investment funds are filling the risk-return gapHybrid long-short funds rival debt, arbitrage and hybrid funds, but look beyond the label.
- Up in the air! Can SBI Funds Management IPO investors look past OFS to expect strong listing day gains?SBI Funds Management's large IPO presents a valuation opportunity for investors. The offer for sale structure may temper immediate listing ...
- Arihant Capital announces launch of Arihant Bharat Advantage Fund, a Category III AIFArihant Capital Markets has launched the Arihant Bharat Advantage Fund, a Category III AIF focused on investing in high-potential companies...
- Buy Wipro for target of Rs 450-465:ArihantArihant Capital Market has advised traders to buy Wipro for target of Rs 450-465.
- Buy BHEL for target of Rs 2455: ArihantArihant Capital Market has advised traders to buy BHEL for target of Rs 2455.
- Buy Reliance Capital for target of Rs 820-835: ArihantArihant Capital Market has advised traders to buy Reliance Capital for target of Rs 820-835.
- Buy Reliance for target of Rs 1135-1180: ArihantArihant Capital Market has advised traders to buy Reliance for target of Rs 1135-1180.
- Buy Ranbaxy for target of Rs 458-465: ArihantArihant Capital Markets has advised traders to buy Ranbaxy Laboratories for target of Rs 458-465.
Load More
